PAVmed Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $71.0K | $3.0M | $2.5M | $377.0K | $500.0K | — | — |
| Cost of Revenue | — | $218.0K | $4.8M | $6.4M | $3.6M | $585.0K | — | — |
| Gross Profit | — | $-147.0K | $-1.8M | $-3.9M | $-3.2M | $-85.0K | — | — |
| Gross Margin | — | -207.0% | -61.3% | -156.8% | -858.6% | -17.0% | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $4.5M | $5.9M | $14.3M | $25.3M | $19.8M | $11.0M | $6.6M |
| SG&A Expense | — | $16.3M | $24.5M | $30.9M | $41.4M | $25.4M | $9.6M | $7.7M |
| Operating Income | — | $-21.8M | $-44.5M | $-68.8M | $-91.1M | $-54.4M | $-23.4M | $-14.3M |
| Operating Margin | — | -30,712.7% | -1,482.9% | -2,751.8% | -24,161.0% | -10,878.6% | — | — |
| Interest Expense | — | — | $45.0K | $589.0K | $1.3M | — | $53.0K | $33.0K |
| Pretax Income | — | $-2.5M | $28.4M | $-79.3M | $-103.2M | $-56.1M | $-35.9M | $-17.3M |
| Income Tax Expense | — | $0 | $0 | — | — | — | — | — |
| Net Income | — | $401.0K | $39.8M | $-64.2M | $-89.0M | $-50.3M | $-34.3M | $-16.5M |
| Net Margin | — | 564.8% | 1,326.4% | -2,567.0% | -23,602.9% | -10,069.4% | — | — |
| EPS (Basic) | — | $-5.63 | $99.15 | $-9.16 | $-15.03 | $-0.65 | $-0.72 | $-0.54 |
| EPS (Diluted) | — | $-5.63 | $14.90 | $-9.16 | $-15.03 | $-0.65 | $-0.72 | $-0.54 |
| Shares Outstanding (Basic) | 6.4M | 670.5K | 322.4K | 7.2M | 5.9M | 77.5M | 63.8M | 40.5M |
| Shares Outstanding (Diluted) | 6.4M | 670.5K | 2.2M | 7.2M | 5.9M | 77.5M | 63.8M | 40.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |